Evidence map›Paper›PMID 39467964›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

Treatment approaches and survival outcomes in elderly colorectal cancer patients: a single-center comparative study.

Beliz Bahar Karaoğlan, Erman Akkuş, Mehmet Kayaalp, Cihangir Akyol, Ayhan Bülent Erkek, Hakan Akbulut, Güngör Utkan

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Beliz Bahar KaraoğlanDepartment of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Türkiye. bbaharulas@gmail.com.ORCID http://orcid.org/0000-0002-5021-7588
Erman AkkuşDepartment of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Türkiye.
Mehmet KayaalpDepartment of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Türkiye.
Cihangir AkyolDepartment of Surgery, Faculty of Medicine, Ankara University, Ankara, Türkiye.
Ayhan Bülent ErkekDepartment of Surgery, Faculty of Medicine, Ankara University, Ankara, Türkiye.
Hakan AkbulutDepartment of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Türkiye.
Güngör UtkanDepartment of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGeriatric patients account for nearly half of new colorectal cancer (CRC) cases. This study compares clinicopathological features, treatments, outcomes, and frailty in elderly (≥ 70) and younger (< 70) CRC patients at our center. MATERIALS AND

methodsPatients diagnosed with non-metastatic or de novo metastatic CRC between January 2015 and April 2024 were included. Demographic, pathological, and survival data were retrospectively collected. Analyses were performed using SPSS version 25, with statistical significance set at P < 0.05.

resultsOf the 414 non-metastatic CRC patients, 26.6% were aged ≥ 70. Elderly patients received less perioperative chemotherapy (60% vs. 81.6%, P < 0.001) and had more dose reductions (41.6% vs. 19.2%, P < 0.001). Frailty reduced perioperative chemotherapy in elderly non-metastatic patients (54.5% vs. 92.1%, P < 0.001) but did not affect dose reduction (37.9% vs. 33.3%, P = 0.764) or treatment duration (median 24 weeks for both groups, P = 0.909). In metastatic patients, frailty shortened chemotherapy duration (9.5 vs. 15.5 weeks, P = 0.129). Elderly patients had lower 5- and 8-year overall survival (OS) rates (64.7%, 60.1% vs. 83.0%, 78.8%, P = 0.004). In the de novo metastatic cohort (135 patients), age did not affect OS (19.4 vs. 17.3 months, P = 0.590) or PFS (9.8 vs. 7.5 months, P = 0.209). Rectal cancer (HR: 2.751, P = 0.005) and early chemotherapy termination (HR: 4.138, P < 0.001) worsened OS in non-metastatic CRC, while absence of RAS (HR: 2.043, P = 0.047), BRAF mutations (HR: 8.263, P = 0.010), and metastasectomy (HR: 3.650, P = 0.036) improved OS in metastatic CRC.

conclusionAge does not independently worsen CRC survival, though early chemotherapy discontinuation impacts outcomes. Reduced-dose chemotherapy or monotherapy can help minimize adverse effects in elderly patients.

Indexed as

Colorectal NeoplasmsAgedAged, 80 and overAge FactorsChemotherapy, AdjuvantFemaleFrailtyHumansMaleMiddle AgedRetrospective StudiesSurvival RateTreatment OutcomeChemotherapy dose reductionColorectal cancerElderlyFrailityGeriatric oncology

Identifiers

PMID39467964

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.